Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
This approval marks a significant milestone in women’s health, introducing Bayer’s first hormone-free treatment for menopause-related symptoms
The Fast Track Designation was supported by nonclinical data as well as clinical results from the ongoing Phase I/IIa trial evaluating the safety and tolerability
Sigachi Industries has reported total income of Rs. 112.97 crore during the period ended September 30, 2025
Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis
Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile
Laurus Labs has reported total income of Rs. 1,680.43 crore during the period ended September 30, 2025
The product is indicated for the chronic management of patients with Urea Cycle Disorders
Glenmark’s Ropivacaine Hydrochloride Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug Naropin Injection of Fresenius Kabi USA
Vaccine efficacy against primary CMV infection ranged from 6 per cent to 23 per cent, depending on case definition, falling short of Moderna’s predefined target
Subscribe To Our Newsletter & Stay Updated
